Hoffmann-la Roche Inc.

Yu-Ching Eugene Pan

Ulrich Andreas Gubler

Maurice Kent Gately

Alvin Seth Stern

Jeffrey David Hulmes

Richard Anthony Chizzonite

Frank John Podlaski

Jarema Peter Kochan

Kuo-Sen Huang

Shirley H Li

Bernard J Scallon

Thomas C Tsang

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto

The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.

Monoclonal antibodies to cytotoxic lymphocyte maturation factor

The present invention involves the protein glycosyl-phosphatidyl-specific phospholipase D (GPI-PLD) in a substantially pure form, an isolated nucleotide sequence encoding GPI-PLD, vectors containing the isolated nucleotide sequence encoding GPI-PLD, and cells transformed by a vector containing the isolated nucleotide sequence encoding GPI-PLD, also nucleotide sequences, vectors and cells comprising hybrid genes with GPI-PLD, and methods for producing secreted proteins.

Glycosyl-phosphatidylinositol-specific phospholipase D

Growing community of inventors

Pine Brook, NJ, United States of America

Yu-Ching Eugene Pan